Syndax Pharmaceuticals (NASDAQ: SNDX) reported Q4 EPS of ($0.78), $0.19 worse than the analyst estimate of ($0.59). Revenue for the quarter came in at $68.7 million versus the consensus estimate of $63.13 million.

For the full year of 2026, the Company expects total research and development plus selling, general and administrative expenses to be approximately $400 million, excluding the impact of $50 million in estimated non-cash stock compensation expense.

For earnings history and earnings-related data on Syndax Pharmaceuticals (SNDX) click here.